Literature DB >> 3490574

Clinical pharmacokinetics of piroxicam.

R K Verbeeck, C J Richardson, K L Blocka.   

Abstract

Piroxicam is readily absorbed after oral administration. Food and antacids have been shown not to interfere with its bioavailability. Piroxicam is highly bound (approximately 99%) to plasma proteins and has a small distribution volume (approximately 10 l). Despite its high plasma binding, the drug readily penetrates into synovial fluid. Piroxicam has a long elimination half-life of about 50 h. Elimination of the parent drug is mainly the result of biotransformation. The elimination of piroxicam is impaired in some elderly patients, resulting in a high interindividual variability in average steady state levels following a standard 20 mg/day dosage regimen.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490574

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

Review 1.  A comparison of synovial fluid concentrations of non-steroidal anti-inflammatory drugs with their in vitro activity.

Authors:  E Urquhart
Journal:  Agents Actions       Date:  1991-03

Review 2.  A Review of Food-Drug Interactions on Oral Drug Absorption.

Authors:  Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

3.  Enhanced elimination of piroxicam by administration of activated charcoal or cholestyramine.

Authors:  D G Ferry; L R Gazeley; W J Busby; D M Beasley; I R Edwards; A J Campbell
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Analysis of piroxicam in pharmaceutical formulation and human urine by dispersive liquid-liquid microextraction combined with spectrophotometry.

Authors:  Ahad Bavili Tabrizi; Nakisa Seyyedeh Tutunchi
Journal:  Adv Pharm Bull       Date:  2013-02-07

5.  The effects of age and gender on the pharmacokinetics of tenidap sodium in patients with rheumatoid arthritis and osteoarthritis.

Authors:  J R Caldwell; D S Kirby; M J Gardner; R A Hansen
Journal:  Br J Clin Pharmacol       Date:  1995       Impact factor: 4.335

6.  Population pharmacokinetic analysis of meloxicam in rheumatoid arthritis patients.

Authors:  Ingolf Meineke; Dietrich Türck
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

7.  Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam.

Authors:  C J Richardson; K L Blocka; S G Ross; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  The pharmacokinetics of piroxicam in elderly persons with and without renal impairment.

Authors:  A C Rudy; N L Figueroa; S D Hall; D C Brater
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

9.  Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam.

Authors:  C Benveniste; R Striberni; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  The consequences of H2 receptor antagonist--piroxicam coadministration in patients with joint disorders.

Authors:  P A Milligan; P E McGill; C W Howden; A W Kelman; B Whiting
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.